This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
1952: American computer scientist Grace Hopper completed what is considered to be the first compiler, a program that allows a computer user to use a human-readable high-level programming language instead of machine code. It was known as the A-0 compiler. 1952: Photograph 51, an X-ray diffraction image of crystallized DNA, was taken by Raymond Gosling in May 1952, working as a PhD student under the supervision of British chemist and biophysicist Rosalind Franklin; it was critical evidence in identifying the structure of DNA. 1952: Canadian agriculturalist Mary MacArthur became the first female Fellow of the Agricultural Institute of Canada for her contributions to the science of food dehydration and freezing. 1952: American physician, obstetrical anesthesiologist and medical researcher Virginia Apgar devised the Apgar score, a way to quickly assess the health of a new-born child immediately after birth in order to combat infant mortality. 1953: Canadian-British radiobiologist Alma Howard co-authored a paper proposing that cellular life transitions through four distinct periods. This became the first concept of the cell cycle. 1954: New Zealand botanist Lucy Cranwell was the first female recipient of the Hector Medal from the Royal Society of New Zealand. She was recognized for her pioneering work with pollen in the emerging field of palynology. 1955: Scottish-Canadian Arctic ice researcher Moira Dunbar became the first female glaciologist to study sea ice from a Canadian icebreaker ship.
The National Economic Council (NEC) in Pakistan is a constitutional entity tasked with evaluating the nation's economic state and devising strategies to promote equitable development and regional balance. Functioning within the framework of Article 156 of the Constitution of Pakistan, it plays a vital advisory role to both federal and provincial governments on matters pertaining to finance, commerce, social welfare, and economic policies.
=== Peripheral edema and hypoalbuminemia === Kwashiorkor is a form of protein deficiency, which can result in both osmotic imbalances and irregularities in the lymphatic system. Kwashiorkor is most notable for peripheral edema. The presence of edema in kwashiorkor is correlated with very low albumin concentration (hypoalbuminemia). Edema results from a loss of fluid balance between the hydrostatic and oncotic pressures across the capillary blood vessel walls due to the lack of protein which affects the body's ability to draw fluid from the tissues into the bloodstream. Low albumin concentration influences negatively the strength of oncotic pressure. Failure leads to fluid buildup in the abdomen, resulting in edema and belly distension. Furthermore, the release of antidiuretic hormone is stimulated by hypovolemia, also leading to the development of peripheral edema. Plasma renin is also stimulated, promoting sodium retention. It is important to distinguish the pathophysiology of marasmus and kwashiorkor when it comes to treating malnourished children who may have hypovolemic shock that is caused by an acute loss of salt and water. Children with severe albumin deficiency struggle physiologically to maintain their blood volume.
== Medical uses == Tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. In the United States, tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Paxillosida (7 families, 48 genera, 372 species) This is a primitive order whose members do not extrude their stomach when feeding and both anus and tube feet suckers are absent. Papulae are present on their aboral surface, and they possess marginal plates and paxillae. They mostly inhabit soft substrates. There is no brachiolaria stage in their larval development. The comb starfish (Astropecten polyacanthus) is a member of this order. Spinulosida (1 family, 8 genera, 121 species) Most species in this order lack pedicellariae; all have a delicate skeletal arrangement with small or no marginal plates on the disc or arms. They have numerous groups of short spines on the aboral surface.
Sources: en.wikipedia.org
== Biography == Born at Port Stanley in 1942 to New Zealanders Harold and Moya (née Boak) Baker, he spent his early life in the Falkland Islands, where his father was the superintendent of education. The family returned to New Zealand in 1948. He was educated at King's College, Auckland from 1956 to 1960. After studying chemistry at the University of Auckland, completing his PhD in 1967, he conducted postdoctoral research on the structure of insulin with Nobel laureate Dorothy Hodgkin at the University of Oxford. He then took up an academic post at Massey University, where he determined the structure of the kiwifruit enzyme actinidin. In 1997 he moved back to the University of Auckland where he became professor of structural biology and later direct of the Maurice Wilkins Center for Molecular Diversity. He also served as president of the International Union of Crystallography between 1996 and 1999. Baker was elected a Fellow of the Royal Society of New Zealand in 1987, and won the society's Hector Medal in 1997. He was awarded the Rutherford Medal, the highest honour in New Zealand science, in 2006. In the 2007 Queen's Birthday Honours, he was appointed a Companion of the New Zealand Order of Merit, for services to science.
== Biosynthesis == The means by which bacteria construct enediynes like kedarcidin continues to motivate research. Kedarcidin chromophore, beyond the carbocyclic core it shares with other enediynes, presents additional biosynthetic puzzles: The relative stereochemistry of the groups appended to the carbocyclic core of kedarcidin chomophore differs from that of closely related enediynes; the (R)-2-aza-3-chloro-β-tyrosine substructure has not been identified in any other known natural product; and despite its seeming simplicity, little literature precedence exists for the biosynthesis of the isopropoxy substituent of the naphthonate group.
=== Casting === In February 2025, Jessica Lange, who starred in the first four seasons and briefly appeared in the eight season in 2018, answered a question about her potential return for the thirteenth season: "Oh Christ, no. I mean, I haven't done it for more than 10 years, 12 years, so, no, I'm not doing it." Murphy revealed that Lange was the first person he turned to about the return and she agreed under the condition she would have a musical number. Subsequently, he turned to Sarah Paulson and Evan Peters, who agreed instantly. They both last appeared in the tenth season in 2021. In October 2025, Lange, Paulson, Peters, Emma Roberts, Billie Lourd, Kathy Bates, Angela Bassett, Leslie Grossman, Jessica Lange, and Gabourey Sidibe were all confirmed to return for the thirteenth season, along with the newcomer Ariana Grande. Bates, Bassett and Sibide last appeared in the eight season in 2018. Bates revealed that she would have only one day of filming. In February 2026, John Waters joined the cast, while Joey Pollari joined in April, and Alex Consani and Paul Anthony Kelly joined in May. John Carroll Lynch and Matt Fraser were also confirmed to reprise their roles from Freak Show, with Mena Suvari and Berto Colón also joining the cast. In July, Frances Conroy was confirmed to reprise her role from Coven, with Avantika, Grace Dumdaw, Cara Delevingne, and Charlie Carver also joining the cast. In July 2026, it was reported that Grande dropped out due to scheduling conflicts with the season's production schedule and her Eternal Sunshine Tour.
The trivial (non-systematic) name for alkanes is "paraffins". Together, alkanes are known as the "paraffin series". Trivial names for compounds are usually historical artifacts. They were coined before the development of systematic names, and have been retained due to familiar usage in industry. Cycloalkanes are also called naphthenes. Branched-chain alkanes are called isoparaffins. "Paraffin" is a general term and often does not distinguish between pure compounds and mixtures of isomers, i.e., compounds of the same chemical formula, e.g., pentane and isopentane.
Sources: en.wikipedia.org
The Unitized Group Ration – A (UGR-A) is the successor to the A-ration, and consists of perishable entrées intended to be prepared in a field kitchen. The UGR-A is the only UGR with frozen food, and requires refrigeration to store and prepare. The UGR-A has 7 breakfast menus and 14 lunch/dinner menus. Each meal provides an average of 1,450 kcal. Each UGR-A module contains 50 meals, with each pallet holding 600 meals. UGR-A modules have a minimum shelf life of 9 months outside the contiguous U.S. and 3 months within the contiguous U.S., at 80 °F (26.6 °C) for semi-perishable modules and 0 °F (-17.7 °C) for perishable modules.
The company was founded by Herbert Hyman (1931–2014) in September 1963, as a coffee service for offices. His wife Mona (whom he married in 1966) and he honeymooned in Sweden where they discovered quality coffee. This sparked the decision to import, roast and sell gourmet coffee in Los Angeles, opening the first Coffee Bean store in 1968 in the Los Angeles neighborhood of Brentwood. Innovations included selling whole beans and touting their country of origin and allowing customers to observe the beans being roasted and then to sample varieties before making a purchase. By the 1970s the firm had expanded to 10 stores in Southern California and had added exotic teas to the menu. In the summer of 1987 an employee brought a blender to a Westwood store where he mixed together ice, coffee extract and chocolate powder, paving the way for the company's signature Ice Blended drinks. With the invention of the Ice Blended, the chain saw a surge in popularity. The drink was a predecessor to the Starbucks Frappuccino. In 1991, when it was first planning to expand into Los Angeles, Starbucks tried to purchase the firm, but Hyman turned them down. The opening of Starbucks stores in Los Angeles unexpectedly helped Coffee Bean's business, by driving curious customers to the area. In 1996, the Hymans sold the Asian franchise rights to Singaporean brothers Victor Sassoon and Sunny Sassoon. The Sassoons quickly expanded the company in the US and internationally, opening the first outlet in Singapore in 1996, and in Malaysia the following year.
== History == Dihexa was developed by Joseph Harding and his team at Washington State University. Later developments were done by M3 Biotechnology, a company founded to commercialize dihexa. Fosgonimeton, a phosphate pro-drug of dihexa is currently in clinical trials for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease
== Medical usage == Sermorelin was used to treat children with growth hormone deficiency or growth failure by stimulating the pituitary gland to release growth hormone (GH), thereby increasing plasma GH levels.
Meinhard I 1253–1258, also Count of Gorizia since 1231 Meinhard II 1258–1295, also Count of Gorizia until 1271, Duke of Carinthia and Margrave of Carniola from 1286, jointly with: Albert V 1258–1271, brother, also Count of Gorizia until 1304 Albert VI, son, until 1292 Henry II 1295–1335, son of Meinhard II, also Duke of Carinthia, King of Bohemia 1306 and 1307–1310, jointly with his brothers Louis, until 1305 Otto, until 1310 Male line extinct, Countess Margaret, daughter of Henry II, married to:
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.